Brokerages expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to announce earnings per share of ($2.74) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Esperion Therapeutics’ earnings, with the highest EPS estimate coming in at ($2.33) and the lowest estimate coming in at ($3.06). Esperion Therapeutics reported earnings of ($3.89) per share in the same quarter last year, which would suggest a positive year over year growth rate of 29.6%. The company is scheduled to issue its next earnings report on Tuesday, February 22nd.
On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($10.56) per share for the current fiscal year, with EPS estimates ranging from ($10.85) to ($10.09). For the next fiscal year, analysts anticipate that the business will post earnings of ($5.14) per share, with EPS estimates ranging from ($7.95) to ($3.92). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, November 2nd. The biopharmaceutical company reported ($2.62) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $0.24. During the same quarter in the prior year, the company posted ($3.07) earnings per share.
NASDAQ ESPR opened at $7.69 on Thursday. Esperion Therapeutics has a 12 month low of $6.97 and a 12 month high of $39.49. The stock has a market cap of $223.60 million, a PE ratio of -0.66 and a beta of 0.91. The stock’s 50 day moving average is $10.10 and its 200 day moving average is $15.34.
Hedge funds have recently modified their holdings of the stock. Independent Advisor Alliance purchased a new stake in shares of Esperion Therapeutics during the third quarter valued at $139,000. Royal Bank of Canada increased its position in shares of Esperion Therapeutics by 70.1% during the second quarter. Royal Bank of Canada now owns 6,550 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,699 shares during the period. Invesco Ltd. raised its stake in shares of Esperion Therapeutics by 19.2% during the third quarter. Invesco Ltd. now owns 12,667 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 2,037 shares in the last quarter. Credit Agricole S A boosted its holdings in shares of Esperion Therapeutics by 49.0% in the second quarter. Credit Agricole S A now owns 7,300 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 2,400 shares during the period. Finally, Cetera Advisor Networks LLC grew its stake in Esperion Therapeutics by 29.6% in the third quarter. Cetera Advisor Networks LLC now owns 13,025 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,975 shares in the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets.
Featured Story: How does equity income fit into an investing strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.